Title:
メラノコルチン４受容体経路関連障害を治療する方法
Document Type and Number:
Japanese Patent JP6940853
Kind Code:
B2
Abstract:
The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist.
Inventors:
Van der Proof, Leonardus H. Tea.
Henderson, Bart
Kuenen, Peter
Henderson, Bart
Kuenen, Peter
Application Number:
JP2018517270A
Publication Date:
September 29, 2021
Filing Date:
September 29, 2016
Export Citation:
Assignee:
Rhythm Pharmaceuticals, Incorporated
Charite-Uniberges The Medicin Berlin
Charite-Uniberges The Medicin Berlin
International Classes:
A61K38/12; A61P3/04; A61P25/00; A61P43/00
Foreign References:
| WO2013102047A1 |
Other References:
Rhythm initiates two phase 2 clinical trials of setmelanotide (RM-493) in rare genetic disorders of obesity caused by MC4 pathway deficiencies,BioSpace,2015年06月04日,https://www.biospace.com/article/releases/rhythm-initiates-two-phase-2-clinical-trials-of-setmelanotide-rm-493-in-rare-genetic-disorders-of-obesity-caused-by-mc4-pathway-deficiencies-/,
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto